Search company, investor...

Founded Year

2001

Stage

IPO | IPO

Total Raised

$103M

Date of IPO

1/31/2013

Market Cap

0.00B

About Humanigen

Humanigen is a clinical-stage biopharmaceutical company with a focus on preventing and treating an immune hyper-response known as 'cytokine storm'. The company's main offerings include the development of a first-in-class antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), which is believed to be a key regulator of many inflammatory cytokines and chemokines involved in the cytokine storm. Humanigen primarily serves the healthcare sector, particularly in areas related to infectious diseases and cancer. It was founded in 2001 and is based in Brisbane, California.

Headquarters Location

1000 Marina Boulevard Suite 250

Brisbane, California, 94005,

United States

650-243-3100

Loading...

Loading...

Humanigen Patents

Humanigen has filed 48 patents.

The 3 most popular patent topics include:

  • clusters of differentiation
  • immunology
  • immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/2/2018

6/13/2023

Clusters of differentiation, Immune system, Immunology, Transcription factors, Cytokines

Grant

Application Date

10/2/2018

Grant Date

6/13/2023

Title

Related Topics

Clusters of differentiation, Immune system, Immunology, Transcription factors, Cytokines

Status

Grant

Latest Humanigen News

Delisting of Securities of Humanigen, Inc.; Vinco Ventures, Inc.; Liquid Media Group Ltd.; Republic First Bancorp, Inc.; G Medical Innovations Holdings Ltd.; Orbital Infrastructure Group, Inc.; Spark Networks SE; DIRTT Environmental Solutions Ltd.; Chenghe Acquisition Co.; mCloud Technologies Corp.; VIQ Solutions Inc.; Capstone Green Energy Corporation; and Histogen Inc. from The Nasdaq Stock Market

Oct 11, 2023

New York, New York, UNITED STATES NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of Humanigen, Inc. Humanigen, Inc.’s securities were suspended on July 26, 2023, and have not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the common stock of Vinco Ventures, Inc. Vinco Ventures, Inc.’s securities were suspended on July 28, 2023, and have not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the common shares of Liquid Media Group Ltd. Liquid Media Group Ltd.’s securities were suspended on August 23, 2023, and have not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the common stock of Republic First Bancorp, Inc. Republic First Bancorp, Inc.’s securities were suspended on August 23, 2023, and have not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the ordinary shares warrants of G Medical Innovations Holdings Ltd. G Medical Innovations Holdings Ltd.’s securities were suspended on August 24, 2023, and have not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the common stock of Orbital Infrastructure Group, Inc. Orbital Infrastructure Group, Inc.’s securities were suspended on August 29, 2023, and have not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the securities of Spark Networks SE. Spark Networks SE’s securities were suspended on September 8, 2023, and have not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the common shares of DIRTT Environmental Solutions Ltd. DIRTT Environmental Solutions Ltd.’s securities were suspended on September 15, 2023, and have not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the warrants of Chenghe Acquisition Co. Chenghe Acquisition Co.’s warrants were suspended on September 21, 2023, and have not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the securities of mCloud Technologies Corp. mCloud Technologies Corp.’s securities were suspended on September 29, 2023, and have not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the common shares of VIQ Solutions Inc. VIQ Solutions Inc.’s securities were suspended on October 5, 2023, and have not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the common stock of Capstone Green Energy Corporation. Capstone Green Energy Corporation’s securities were suspended on October 5, 2023, and have not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the common stock of Histogen Inc. Histogen Inc.’s securities were suspended on October 5, 2023, and have not traded on Nasdaq since that time. For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com. Nasdaq’s rules governing the delisting of securities can be found in the Nasdaq Rule 5800 Series, available on the Nasdaq Web site: https://listingcenter.nasdaq.com/rulebook/nasdaq/rules/nasdaq-5800-series .

Humanigen Frequently Asked Questions (FAQ)

  • When was Humanigen founded?

    Humanigen was founded in 2001.

  • Where is Humanigen's headquarters?

    Humanigen's headquarters is located at 1000 Marina Boulevard, Brisbane.

  • What is Humanigen's latest funding round?

    Humanigen's latest funding round is IPO.

  • How much did Humanigen raise?

    Humanigen raised a total of $103M.

  • Who are the investors of Humanigen?

    Investors of Humanigen include MidCap Financial, Sofinnova Ventures, GBS Venture Partners, Clarus, Alloy Ventures and 11 more.

  • Who are Humanigen's competitors?

    Competitors of Humanigen include Invistics, Acorda Therapeutics, Crown Bioscience, Deciphera Pharmaceuticals, Molecular Templates and 7 more.

Loading...

Compare Humanigen to Competitors

H
Harkness Pharmaceuticals

Harkness Pharmaceuticals is focused on developing anti-obesity therapeutics. Per the company, currently more than 20% of the U.S. population are considered clinically obese yet there remain few therapeutic option available. Harkness is performing exploratory human clinical trials in collaboration with the Pennington Institute in Louisiana.

A
Ansata Therapeutics

Founded in early 2002 by Avalon Ventures and Domain Associates, Ansata Therapeutics is developing & commercializing novel medicines that capitalize on the Company's industry- leading expertise and intellectual property in molecular transduction. Ansata has several preclinical programs under development in the oncology and neurodegenerative disease areas. The company strives to rapidly advance lead compounds from late-stage preclinical research into clinical development by leveraging its proprietary knowledge of common dermatological diseases.

AdAlta Logo
AdAlta

Which is using a platform-technology approach to develop antibody and peptide-based therapeutics against select targets.

M
ModiQuest

ModiQuest (CRO) focus is on generation of recombinant monoclonal antibodies (animal, human). The company use antigen specific B-cell selection combined with efficient hybridoma generation or direct antibody cDNA cloning from selected B-cells. MQR offers custom phage display services.

N
NeuroMolecular Pharmaceuticals

NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.

C
Calyx Therapeutics

Calyx Therapeutics is a pharmaceutical company focusing on oral therapies for diabetes and inflammatory diseases. Calyx utilizes natural plant extracts with demonstrated clinical activity in humans as the source of its discovery efforts. The company isolates the biologically active molecule, determines its chemical structure, and aims to develop small molecule analogs. This process aims to reduce the time and investment required to take lead molecules into preclinical and clinical testing.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.